TotalMarketCap

Galectin Therapeutics

GALTNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$301.196 M

$2.98 -14.12%

Close of 6 Nov 2026

As of 6 Nov 2026, Galectin Therapeutics (GALT) has a market capitalization of $301.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$30.8M

Loss-making

Shares outstanding

100,849,644

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #216Opus GeneticsIRD$334.0M
  2. #217Benitec BiopharmaBNTC$303.2M
  3. #218Galectin TherapeuticsGALT$301.2M
  4. #219Emergent BioSolutionsEBS$300.0M
  5. #220Enanta PharmaceuticalsENTA$294.2M

What if Galectin Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$279,372.18

Per share 93,749× higher

Bitcoin $1.53T

$15,116.34

Per share 5,073× higher

Apple $5.02T

$49,625.54

Per share 16,653× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Galectin Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.